The Cellular Insider How Antibodies Command the TRIM21 Protein to Devour Invading Pathogens from Within

Every day, the human body confronts countless pathogens. While most people envision the classic immune picture—antibodies patrolling the bloodstream and white blood cells swarming invaders—the reality is far more complex. Many pathogens successfully evade this first line of defense, slipping into healthy cells to set up camp. Once inside, they often remain safely out of reach of conventional immunological weapons. Does this mean our cells are left completely defenseless?

Not at all. In a study recently published in the international journal Molecular Cell, titled "TRIM21 induces selective autophagy of viruses and bacteria," researchers from the MRC Laboratory of Molecular Biology (LMB) and collaborating institutions unveiled a brand-new intracellular defense mechanism termed "Antibody-Directed Xenophagy" (ADX). This mechanism can identify and eliminate bacteria and viruses—including Salmonella and adenoviruses—that have already breached the cell membrane. It functions much like a local militia organizing an effective street-by-street guerrilla defense after enemy forces have broken through the city gates.

Through a genome-wide phenotypic screen, the researchers identified the core commander of this process: a highly versatile ubiquitin ligase known as the TRIM21 protein. When an antibody-coated pathogen enters a cell, TRIM21 rapidly recognizes and binds to the antibody-pathogen complex. It then activates its ubiquitination machinery, slapping an "enemy" tag onto the invader. These ubiquitin tags are subsequently recognized by cellular autophagy receptors, which engulf the pathogen and transport it to the lysosome for destruction. The entire sequence, from initial viral or bacterial invasion to clearance, is remarkably swift and efficient.

Figure 1. TRIM21 rapidly intercepts cell-invading virions. (Rhinesmith T, et al., 2026)

Traditional dogma holds that antibodies function primarily in the extracellular space. The existence of TRIM21 upends this textbook view, proving that antibodies can accompany pathogens inside the cell to serve as "navigation beacons" for intracellular immunity. Using quantitative microscopy, the research team captured the entire sequence: TRIM21 intercepting the antibody-pathogen complex, recruiting autophagy adapter proteins, and ultimately delivering the cargo to the lysosome.

Even more striking is the remarkably broad antimicrobial spectrum of ADX. Experiments demonstrated that this mechanism restrains not only non-enveloped viruses like adenoviruses but also intracellular bacteria like Salmonella. In mouse models, the ADX pathway significantly mitigated tissue damage and bacterial invasion caused by Salmonella. Furthermore, because TRIM21 is encoded by an interferon-stimulated gene (ISG), its expression levels are further ramped up during an infection. It is also detectable across nearly all cells and tissues in the body. In other words, the human body has pre-installed this "built-in" defensive weapon within every single cell.

This study marks the first time scientists have mapped out the complete chain of evidence for ADX—bridging molecular mechanisms, cellular functions, and physiological relevance in vivo. Beyond discovering this novel pathway, the researchers demonstrated that TRIM21 plays an irreplaceable role; without it, protective immunity against viruses is significantly compromised. This strongly suggests that ADX is not merely an immunological "backup tire," but a primary line of defense that stands shoulder-to-shoulder with classic immunity.

Granted, whether TRIM21 acts as the sole executor of ADX, and whether it faces limitations in its recognition range, remain questions for future exploration. However, this discovery undoubtedly opens a radically new vantage point on how the human body fights infection. In the future, scientists might engineer specific antibodies or small-molecule drugs to artificially tag pathogens. This would allow TRIM21 to recognize them earlier and more precisely, triggering ADX to pioneer entirely new anti-infective therapeutic strategies. As humanity faces the growing threat of antibiotic resistance, mobilizing the cell's own "insider" forces may offer a highly promising path forward.